Xorte logo

News Markets Groups

USA | Europe | Asia | World| Stocks | Commodities



Add a new RSS channel

 
 


Keywords

2025-07-02 07:43:04| The Economic Times

AstraZeneca Pharma India shares saw a rise after Imfinzi got approval for expanded use. The CDSCO approved it as a first-line treatment for specific endometrial cancer cases. This follows AstraZeneca's strong Q4 earnings, with a significant jump in net profit and revenue. The company attributes this to its focus on innovation.


Category: News and Media

 

LATEST NEWS

2025-07-02 07:37:00| The Economic Times

Decades after the Dalai Lama's exile following a failed uprising, Tibetans will gather to celebrate his 90th birthday on July 6.


Category: News and Media

 

2025-07-02 07:33:15| BBC News | Business | World Edition

MPs approved the Universal Credit and Personal Independence Payment Bill but only after ministers made big changes.


Category: News and Media

 

Latest from this category

03.07Happy Square Outsourcing IPO opens today: Check details
03.07Gold falls after US-Vietnam trade deal; US payroll data eyed
03.07Startups aim for over Rs 18,000 crore in D-Sreet dhamaka
03.07Can HDB Financial Services maintain its momentum after a strong IPO listing?
03.07Has gold reached its peak? Economists weigh in on future price trends
03.07Key strength ratio signals bullish momentum for Indian markets
03.07Microsoft to cut up to 9,000 jobs as it invests in AI
03.07Why the world's superyachts are getting bigger and bigger
News and Media »

All news

03.07Thursday Watch
03.07Happy Square Outsourcing IPO opens today: Check details
03.07Gold falls after US-Vietnam trade deal; US payroll data eyed
03.07Startups aim for over Rs 18,000 crore in D-Sreet dhamaka
03.07Can HDB Financial Services maintain its momentum after a strong IPO listing?
03.07Has gold reached its peak? Economists weigh in on future price trends
03.07Key strength ratio signals bullish momentum for Indian markets
03.07Microsoft to cut up to 9,000 jobs as it invests in AI
More »
Privacy policy . Copyright . Contact form .